Allergan announced it is launching a direct-to-consumer (DTC) broadcast TV advertising campaign for Restasis (cyclosporine ophthalmic emulsion) 0.05%, launching April 2021.
Restasis has been FDA approved for 17 years and is the #1 dispensed branded eye drop, prescribed for over 7.6 million patients [1-3].* However, the need to drive awareness of this chronic condition is still immense. That’s why Restasis is back on TV, according to Allergan.
The tone of the new 60-second Restasis spot is one of empowerment. It features a resourceful woman taking on challenging projects. In the commercial, viewers will hear a clear call to action encouraging patients to take that can-do spirit and apply it by talking to their doctor.
Restasis and Restasis Multidose ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
1. Symphony Health, PHAST Prescription Monthly, data through October 2016.
2. Symphony Health, PHAST Prescription Monthly, data through October 2019.
3. *IQVIA, Xponent PlanTrak, January 2019-October 2019.